ClinicalTrials.gg
RecruitingNCT07010146Updated Jul 17, 2026

Role of Estrogen on Skeletal Outcomes in FHA

A Phase 2 interventional study of transdermal 17β-E2 with cyclic progestin and oral 17β-E2 with cyclic progestin in Bone Strength, Bone Density and FHA (Functional Hypothalamic Amenorrhea), sponsored by University of Virginia. Recruiting at 2 sites in United States. Open to female participants aged 14 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by University of Virginia · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
14 Years to 30 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Planned enrollment
6th of 30
150 · median 37
Started
2025
with 3 others
Phase 2
9 of 43
2 open now
Registered
40th of 43
by date

Among the 43 studies in Amenorrhea with a site in United States, this one is the 6th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 in phase 2, and was the 40th registered.

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 14 Years to 30 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess whether the natural form of estrogen (17-beta estradiol) given as a patch so that it is absorbed through your skin, is better at improving bone strength over 1 year than natural estrogen (17-beta estradiol) taken by mouth, or a synthetic form oestrogen (ethinyl estradiol) given as a patch that also provides birth control.

Participants will:

  1. Take estrogen for 1 year either (i) in its natural form as a patch twice a week (and progesterone by mouth for 12 days of each month), or (ii) in its natural form as a pill daily (and progesterone by mouth for 12 days of each month), or (iii) in a synthetic form as a birth control patch weekly for 3 weeks with 1 week off the patch. You will not be able to choose which form of estrogen you will receive as this will be assigned to you based on a pre-existing randomization sequence (like the flip of a coin)
  2. Take provided calcium and vitamin D supplements
  3. Attend 4 study visits over 12 months with two at the beginning and then every 6 months that include:

    • History and Physical Exams
    • Lab Work
    • Imaging studies
    • Questionnaires
    • Dietary recalls
Read the detailed description

Low bone mass is a major co-morbid complication of functional hypothalamic amenorrhea (FHA) in adolescents and young adult women, including those with anorexia nervosa (AN) and exercise-induced amenorrhea (EIA), and the prevalence of fractures is markedly higher than in normal-weight controls (43% in EIA, 38% in AN vs. 22% in controls).1 Adolescence and young adulthood are a critical time for bone accrual. Peak bone mass, a major determinant of bone mineral density (BMD) and fracture risk in adult life, is established between 20-25 years of age in women. Insults to bone accrual during the adolescent and young adult years could result in permanent bone mass deficits, leading to increases in fracture risk. Despite weight regain and menses recovery in some individuals, BMD remains lower than in normal-weight peers, likely because weight recovery is often partial, relapses are common, and not all hormonal alterations contributing to low BMD in FHA completely normalize.2, 3 Thus, additional intervention is necessary to optimize skeletal health.

While many factors contribute to impaired skeletal health in FHA, a key contributor is the associated hypogonadism. Estrogen has anti-resorptive effects on bone through increases in osteoprotegerin and decreases in RANKL and inflammatory cytokines, and bone anabolic effects through inhibition of sclerostin. Yet, estrogen administration as the oral combined estrogen-progestin contraceptive pill is not effective in improving skeletal health4-6 because of hepatic first pass effects resulting in reduction in IGF-1 (a key bone trophic hormone, particularly during adolescence), and increases in SHBG (binding protein of the sex steroids), with a reduction in bioavailable estrogen.6, 7 In contrast, Investigators have demonstrated that transdermal physiologic 17β-estradiol replacement (17β-E2) (with cyclic progestin), which bypasses hepatic first pass metabolism and does not decrease IGF-1 or increase SHBG, increases bone accrual in adolescents and young adults with AN8 and EIA,6 resulting in its incorporation into Endocrine Society Guidelines for FHA management9.

However, transdermal 17β-E2 (with cyclic progesterone) does not have contraceptive efficacy and is not suitable for sexually active young women, unless administered with another mode of contraception (e.g. a progestin releasing IUD), and not always desirable to young women, leading to reduced uptake. The transdermal contraceptive patch containing a non-physiologic form of estrogen (ethinyl estradiol, EE) with a progestin (levonorgestrel, LNG) offers a systemic route of estrogen administration with avoidance of hepatic first pass metabolism. However, it is not known whether this patch is effective in improving skeletal health in FHA. Limited available data suggest otherwise,10 possibly because of an increase in SHBG with EE, despite transdermal administration.11-13 Further, many women prefer an oral pill because of skin irritation with the patch, cosmetic issues, and difficulty remembering to change the patch once or twice a week vs. taking a pill daily. While combined oral contraceptive pills containing EE are not effective in improving bone outcomes, it is not clear whether oral 17β-E2 (a physiologic form of estrogen) could be as effective as transdermal 17β-E2 despite hepatic first pass metabolism. Importantly, oral and transdermal 17β-E2 are often used interchangeably in other hypogonadal states,14 despite some evidence that oral 17β-E2 suppresses IGF-1 and increases SHBG.15, 16 The investigators thus propose a randomized controlled trial (RCT) of 2 mg oral 17β-E2 (with cyclic progesterone) vs. 100 mcg transdermal 17β-E2 (with cyclic progesterone) vs. 30 mcg transdermal EE (with LNG) in young women 14-25 years old with FHA (who are in the process of accruing peak bone mass) to determine whether transdermal 17β-E2 is more effective than oral 17β-E2 or transdermal EE in improving bone outcomes, or whether one or both of the latter two modes of estrogen administration are equivalent to transdermal 17β-E2 in this context. Results from this study could markedly impact clinical management of young women with FHA and potentially allow for alternative forms of estrogen administration in those with FHA.

Aim 1: To characterize the impact of transdermal 17β-E2 (with cyclic progesterone) vs. oral 17β-E2 (with cyclic progesterone) and transdermal EE (with LNG) on bone geometry, structure, density and strength in young women 14-25 years old with functional hypothalamic amenorrhea. Investigators hypothesize that transdermal 17β-E2 will be superior to oral 17β-E2 and transdermal EE in achieving optimal improvement in:

Hypothesis 1A: Areal BMD at the spine, hip and femoral neck; spine trabecular bone score (DXA)

Hypothesis 1B: Volumetric BMD, bone geometry and structure at the distal radius and tibia (HRpQCT)

Hypothesis 1C: Bone strength estimates (assessed using microfinite element analysis)

Aim 2: To determine effects of transdermal 17β-E2 (with cyclic progesterone) vs. oral 17β-E2 (with cyclic progesterone) and transdermal EE+LNG on levels of IGF-1 and SHBG, in relation to markers of bone turnover. Investigators hypothesize that:

Hypothesis 2A: Compared to transdermal 17β-E2, oral 17β-E2 will cause greater decreases in IGF-1, and both oral 17β-E2 and transdermal EE will cause greater increases in SHBG (with decreases in bioavailable estradiol).

Hypothesis 2B: Those with greater decreases in IGF-1 and greater increases in SHBG will demonstrate greater decreases in a bone formation marker (N-terminal propeptide of Type 1 procollagen, P1NP); changes in P1NP will be associated positively with changes in bone variables.

Data resulting from the study will be instrumental in driving recommendations for estrogen replacement in FHA.

Design: 114 young women 14-30 years old with FHA will be randomized in a 1:1:1 fashion to 1 of 3 groups for 12 months (1) 100 mcg transdermal 17β-E2 (with cyclic progesterone) OR (2) 2 mg oral 17β-E2 (with cyclic progesterone) OR (3) transdermal EE+LNG, to determine whether transdermal 17β-E2 is more effective than oral 17β-E2 or transdermal EE in improving bone outcomes, or whether one or both of the latter two modes of estrogen administration are equivalent to transdermal 17β-E2 in this context. All participants with FHA will also receive at least 600 IU of vitamin D and 1000 mg of calcium daily to avoid effects of suboptimal vitamin D concentrations and calcium status on bone endpoints. The study will be randomized, but not blinded (i) because there is a risk of participants assuming they are receiving contraception (with a blinded design) resulting in accidental pregnancies, and (ii) because bone outcomes (unlike e.g. psychological outcomes) are not expected to be impacted by study blinding/unblinding.

Analytical Plan:

The study will be done as intention-to-treat, analyzing changes in bone health at 12 months among participants randomized to the treatment groups. In general, the safety and efficacy populations will be the same, namely, all participants randomized to a treatment.

Participant characteristics at the time of randomization will be tabulated by group. Categorical variables will be summarized by percentages; continuous variables will be summarized by medians and interquartile ranges. No inferential statistical are planned.

Analysis of Aim 1:

Repeated measures models will be used to compare changes in areal BMD at the spine, hip and femoral neck as well as spine trabecular bone score from DXA. Based on published results,6, 69 investigators anticipate the use of a spatial power covariance structure, with equal variances over time and within-subject correlations that are a decreasing function of the time between two measurements within an individual. They will consider other covariance structures, such as those induced by random effects models, if the spatial power covariance assumptions do not seem to hold. Contrasts within the repeated measures model will be used to make comparisons of the primary endpoints both overall and at specific time points. The analyses will be adjusted for age, height, race and ethnicity by including terms for these characteristics in the repeated measures model. Similar analyses will be done for the endpoints in hypotheses 1B and 1C. The analyses will be carried out primarily in SAS 9.4 PROC MIXED. Analysis of the Secondary Endpoint(s): The analyses for hypotheses 2A and 2B are similar to those of the primary endpoint. Contrasts will be used to make specific two-group comparisons of the changes in IGF-1 and SHBG between groups.

03

Conditions studied

  • Bone Strength
  • Bone Density
  • FHA (Functional Hypothalamic Amenorrhea)

Browse trials for

Keywords

  • Estrogen
  • Functional hypothalamic amenorrhea
  • Transdermal
  • Oral
04

Who can participate

Ages eligible
14 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females, age 14-30 years, skeletally mature with bone age ≥ 14 years (only 2% of growth left)
  • Women of reproductive age: use of an effective non-hormonal method or a progestin releasing intrauterine device (no systemic skeletal effects) for study duration if sexually active. Note: Women who receive a progestin implant for contraception after study enrollment will be allowed to continue and will not be excluded from study.
  • Biochemical criteria: negative βHCG (pregnancy test), TSH within 2x the , prolactin \<10 ng/mL above upper limit of normal, potassium between 3.0-5.0, ≤3 times upper limit of normal, LDL ≤190 mg/dl.
  • Patients with known hypothyroidism will be included if appropriately treated with levothyroxine and have a TSH within 2x the upper limit of normal for at least a month preceding the baseline study visit.
  • Menstrual criteria: \< 3 menses in the preceding 6 months.

Exclusion criteria

Exclusion Criteria:

  • Disease other than FHA known to affect bone, including untreated thyroid dysfunction, Cushing's disease, renal failure, diabetes mellitus

    1. Primary thyroid dysfunction will be defined as a TSH level more than 2X the per given reference range with unknown thyroid antibody status, or an abnormal TSH if known positive antibodies.
    2. Patients with hypothyroidism will be excluded if not appropriately treated with levothyroxine and if they do not have a TSH level within 2X the upper limit of normal for at least a month preceding the baseline study visit, given possible effects on the reproductive axis and bone.
  • Use of other medications known to affect bone metabolism within 3 months of the study (other than calcium and vitamin D supplementation)
  • Substance use disorder; current smoker (>10 cigarettes per day)
  • Pregnant, planning to become pregnant within 12 months of the end of treatment and/or breastfeeding
  • Hypertension or use of anti-hypertensive medications
  • Other conditions causing oligo-amenorrhea such as PCOS, premature ovarian insufficiency
  • Known sensitivity or absolute to any component of study medications (high risk thromboembolic disease, breast cancer or other estrogen- or progestin-sensitive cancer, liver tumors, acute viral hepatitis, decompensated cirrhosis, undiagnosed abnormal uterine bleeding
  • ≥ 25 kg/m2 (efficacy of the patch being used in the study is lower at higher BMIs)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    transdermal 17β-E2 with cyclic progestin

    Drug: transdermal 17β-E2 with cyclic progestin

  • Experimental
    oral 17β-E2 with cyclic progestin

    Drug: oral 17β-E2 with cyclic progestin

  • Experimental
    transdermal EE+LNG

    Drug: transdermal EE+LNG

Interventions

  • Drugtransdermal 17β-E2 with cyclic progestin

    100-mcg transdermal 17β-E2 patch (to be applied twice weekly) (continuous use), with 200 mg micronized progesterone given for 12 days of every month

  • Drugoral 17β-E2 with cyclic progestin

    2 mg of oral 17β-E2 pills daily, with 200 mg micronized progesterone given for 12 days of every month

  • Drugtransdermal EE+LNG

    transdermal EE (30 mcg) + LNG (120 mcg) contraceptive patch (TWIRLA). Patch will be applied once a week for 3 consecutive weeks, with the 4th week off the patch (to be repeated after 4 weeks).

06

What researchers measure

Primary outcomes

  1. Areal BMD at the spine, hip and femoral neck as well as spine trabecular bone score from DXA

    Using repeated measures analysis, the investigators will compare change in lumbar spine, total hip and femoral neck BMD and trabecular bone score after 12 months of treatment between the transdermal 17β-E2 group and each of the oral 17β-E2 and transdermal EE+LNG groups. BMD and TBS are assessed using DXA. Unit for BMD is g/cm2.

    Time frame: Baseline and post-treatment (12 months)

  2. 12-month change in volumetric BMD at the radius and tibia

    Using repeated measures analysis, the investigators will compare change in volumetric BMD at the radius and tibia after 12 months of treatment between the transdermal 17β-E2 group and each of the oral 17β-E2 and transdermal EE+LNG groups. Volumetric BMD is assessed using HRpQCT (mgHA/cm3)

    Time frame: Baseline and post- treatment (12 months)

  3. 12-month change in cortical thickness at the radius and tibia

    Using repeated measures analysis, the investigators will compare change in cortical thickness at the radius and tibia after 12 months of treatment between the transdermal 17β-E2 group and each of the oral 17β-E2 and transdermal EE+LNG groups. Cortical thickness is assessed using HRpQCT (mm).

    Time frame: Baseline and post- treatment (12 months)

  4. 12-month change in failure load at the radius and tibia

    Using repeated measures analysis, the investigators will compare change in failure load at the radius and tibia after 12 months of treatment between the transdermal 17β-E2 group and each of the oral 17β-E2 and transdermal EE+LNG groups. Failure load is assessed using microfinite element analysis (N).

    Time frame: Baseline and post- treatment (12 months)

Secondary outcomes

  1. 12-month change in IGF-1

    Using repeated measures analysis, the investigators will compare change in IGF-1 concentrations after 12 months of treatment between the transdermal 17β-E2 group and the oral 17β-E2 group.

    Time frame: Baseline and post-treatment (12 months)

  2. 12-month change in SHBG

    Using repeated measures analysis, the investigators will compare change in SHBG concentrations after 12 months of treatment between the transdermal 17β-E2 group and the transdermal EE+LNG group

    Time frame: Baseline and post-treatment (12 months)

  3. Associations of 12-month change in IGF-1 with changes in P1NP

    The investigators will use rank correlation analysis for this assessment.

    Time frame: 12 months

  4. Associations of 12-month change in SHBG with changes in P1NP

    The investigators will use rank correlation analysis for this assessment.

    Time frame: 12 months

  5. Associations of 12-month change in P1NP with changes on bone endpoints

    The investigators will use rank correlation analysis for this assessment.

    Time frame: 12 monhts

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Primary and secondary endpoint data, including all bone endpoints, will be submitted to the Harvard Dataverse repository to enable other researchers to analyze our study data independently. The privacy, rights, and confidentiality of human research participants will be protected by sharing only de-identified data.

Supporting information: Statistical analysis plan, Informed consent form

Time frame: Data sharing will occur no later than the end of performance period of the extramural award that generated the data. There is no end date planned at this time.

Access criteria: Study investigators will make access to deidentified data available via repository without restriction to access. Data available will include deidentified demographic data and those related to primary and secondary endpoints.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 8, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
May 31, 2030
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07010146
Responsible party
Madhusmita Misra (Professor of Pediatrics, University of Virginia) — Principal investigator
First posted
Jun 8, 2025
Start date
Oct 1, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Jul 17, 2026

Study contacts

Madhusmita Misra, MD, MPH
Contact
madhusmita.misra@uvahealth.org
434-924-9141
Sara Braslow, BA
Contact
EVZ3BW@uvahealth.edu
434-982-4234
Madhusmita Misra, MD, MPH
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion